Abstract: The present invention relates to a pharmaceutical combination comprising a CDK inhibitor and at least one antioxidant enzyme inhibitor for use in the treatment of cancer. The present invention also relates to a method for the treatment of cancer comprising administering to a subject in need thereof, a therapeutically effective amount of a CDK inhibitor and a therapeutically effective amount of at least one antioxidant enzyme inhibitor. The pharmaceutical combination of the present invention exhibits synergistic effect when used in the treatment of cancer.

Abstract: Described herein are methods for modulation of the activity of the carotid body that afford therapeutic benefit for sleep-related breathing disorders and related conditions.

Abstract: The present invention provides methods of stimulating angiogenesis and the growth or migration of cells associated with angiogenesis, by contacting animals, tissues, or cells with sulfide, alone or in combination with nitric oxide. These methods may be used for a variety of purposes, including promoting wound healing, increasing blood flow, and for the treatment and prevention of diseases and disorders associated with decreased blood flow, including ischemic or hypoxic injury.

Abstract: The present invention relates to methods of treating cancer through stasis induction, wherein said stasis-inducing treatment results in reduced blood flow to the cells of said cancer, leading to diminished tumor growth and/or tumor death. In one embodiment, the stasis-inducing treatment comprises administering a therapeutically effective amount of a chalcogenide, salt, or prodrug thereof. The method of treating cancer may optionally comprise an additional step of withdrawing a portion of blood from said patient, such that blood flow to said cancer is further reduced or eliminated. In additional embodiments, the method of treating cancer may optionally comprise an additional step of diverting a portion of the blood flow in said patient, such that blood flow to said cancer is further reduced or eliminated.

Abstract: Methods which increase the bioavailability of beneficial gases in the circulatory system are provided. The methods involve administering agents that changes the binding affinity of a medicinal gas such as NO, CO, H2S, N2O, SO, SO2 and O2 for Hb and/or hemoglobin based oxygen carriers (HBOCs). The change results in increased release of gases carried by Hb and HBOCs. As a result, the concentration of the OH gases in circulation is raised, and they are more available to exert their beneficial effects, e.g. in the treatment of disease or conditions caused by low levels of the gases. The methods are optionally used together with administration of medicinal gases and/or administration of HBOCs and/or other non-HBOC gas carriers such as PFC, and as (or in conjunction with) diagnostic methods.

Abstract: The present invention relates to metal organic framework materials which possess anti-microbial properties. The present invention also provides methods of preparing such metal organic framework materials and uses of the metal organic framework materials to prevent or treat microbial infections, or provide surfaces which limit contamination by micro-organisms.

Abstract: Alterations of redox homeostasis in mammals underlie a host of symptoms, syndromes and diseases, including AIDS and cancer, which can be successfully treated by administration to a mammal of therapeutically-effective amounts of sulfide compounds and/or thiosulfate compounds and/or thionite compounds and/or sulfite compounds and/or thionate compounds and/or any organic, inorganic or organometallic precursors thereof. The unique compositions of this invention contain one or more “active sulfur compounds” in combination with each other or with other therapeutic agents. The invention also encompasses the varying modes of administration of the therapeutic compounds. In particular, a novel method of combining active ingredient with wet cellulose is provided, which allows the wet cellulose to function as an enteric carrier.

Abstract: The present invention generally relates to the modulation of hypoxia-inducible factor (HIF) using the compounds and methods disclosed herein. These compounds and methods can be applied to the prevention, pretreatment, and/or treatment of conditions or states associated with HIF, such as hypoxia- and ischemia-related conditions and the induction of stasis.

Abstract: The present invention provides novel stable, liquid compositions comprising chalcogenides or salts thereof. These compositions may be used for a variety of purposes, including the treatment and prevention of ischemic or hypoxic injury, as well as in the preservation of biological matter.

Abstract: The present invention concerns the use of active compounds, including chalcogenides and sirtuin-modulating compounds, either alone or in combination for increasing or enhancing survivability and/or longevity in biological matter. In general aspects, the chalcogenides and other active compounds may modulate one or more sirtuin proteins. It includes compositions, methods, articles of manufacture and apparatuses for enhancing survivability in any of these biological materials, so as to preserve and/or protect them. In specific embodiments, there are also therapeutic methods and apparatuses for aging or stress, diabetes, obesity, neurodegenerative diseases, cardiovascular disease, blood clotting disorders, inflammation, cancer, organ transplantation, hyperthermia, wound healing, hemorrhagic shock, cardioplegia for bypass surgery, neurodegeneration, hypothermia, and cancer using the active compounds described.

Abstract: Topical administration of a generator of H2S in biological tissues for the treatment of eye disorders, such as glaucoma. NaHS caused a time-dependent decrease in intraocular pressure in normotensive, conscious albino rabbits indicating a similar role for H2S in the regulation of aqueous humor dynamics in animals and humans. H2S donors, NaHS and Na2S, inhibited field-stimulated [3H]NE release from porcine isolated iris-ciliary bodies and produced relaxation of pre-contracted iris muscle strips indicating a pharmacological role for H2S in the anterior uvea. The observation that donors of H2S can alter sympathetic neurotransmission and induce an inhibitory action on iris smooth muscle suggests that this gas has the potential to influence several physiological/pathological processes in the eye. The ability of NaHS or Na2S to inhibit [3H]NE release mimics the well-established action some antiglaucoma drugs (e.g.

Abstract: In this disclosure, a method is described wherein the method comprises mixing a therapeutic gas or a therapeutic liquid or a combination thereof and a liquid carrier in a high shear device to produce a dispersion; and administering the produced dispersion intravenously to a patient; wherein the produced dispersion contains nanobubbles of the therapeutic gas or droplets of the therapeutic liquid with a mean diameter of less than about 1.5 ?m. In this disclosure, a system is also described wherein the system comprises a therapeutic gas source or a therapeutic liquid source or a combination thereof, a liquid carrier source; a high shear device (HSD) having an inlet, an outlet, at least one rotor, and at least one stator separated by a shear gap; and a pump configured to control the flow rate and residence time of a fluid passing through the high shear device.

Abstract: The present invention concerns the use of oxygen antagonists for inducing stasis in tissue, including all or part of organs. It includes methods and apparatuses for achieving stasis in tissue, so as to preserve and/or protect them. In specific embodiments, preservation methods and apparatuses for preserving tissue for transplantation purposes is provided.

Abstract: Patients having a disease associated with high level of thioredoxin system activity or a requirement for nitric oxide, e.g. large cell lymphoma or restenosis, are treated with a thioredoxin reductase inhibitor, e.g. auranofin or arsenic trioxide, and a nitric oxide donating compound, e.g. isosorbide mononitrite or isosorbide dinitrite or nitroglycerin or S-nittrosothiol. Patients having a disease associated with nitric oxide synthase overexpression or increased activity, e.g. Parkinson's disease or septic shock or pancreatic cancer, are treated with Trx/Trx reductase upregulator, e.g. aptamer that binds to thioredoxin reductase inhibitor, and agent causing depletion of nitric oxide (or adduct thereof), e.g. L-NMMA or L-NAME or minocycline or ascorbate or N-acetylcysteine.

Abstract: The present invention provides novel stable, liquid compositions comprising chalcogenides or salts thereof. These compositions may be used for a variety of purposes, including the treatment and prevention of ischemic or hypoxic injury, as well as in the preservation of biological matter.

Abstract: This invention is for a method of treatment of rabies once the patient develops signs and symptoms of rabies with the intent to save the patients from death and disability using insulin combined with various anti rabies viral therapeutic, pharmaceutical, biochemical, and biological agents or compounds with added supportive therapies administered through OM, SAS, IVB, IV, and IA routes. An embodiment provides devices for intranasal delivery of therapeutic agents to olfactory mucosal area. Another embodiment uses the technology to deliver the therapeutic, pharmaceutical, biochemical, and biological agents or compounds to the subarachnoid space and ventricular system by using continuous catheters and Ommaya reservoir at the same time. The present method incorporates breaking the blood brain barrier to allow the entry of the anti rabies therapeutic agents into the neuropile. Additionally, an embodiment incorporates cooling of the brain and inducing hibernation to preserve the brain from damage due to rabies.

Abstract: The present invention provides methods of stimulating angiogenesis and the growth or migration of cells associated with angiogenesis, by contacting animals, tissues, or cells with sulfide, alone or in combination with nitric oxide. These methods may be used for a variety of purposes, including promoting wound healing, increasing blood flow, and for the treatment and prevention of diseases and disorders associated with decreased blood flow, including ischemic or hypoxic injury.

Abstract: A method of making PVA microbubbles including a functionalisation step in which PVA polymeric chains are functionalised at their ends with aldehyde groups, and a subsequent cross-linking step, in which in an air-aqueous solution emulsion with a pH between 4.5 and 5.5 the previously functionalised PVA polymeric chains cross-link by means of an acetalisation reaction, thereby forming the microbubbles. The microbubbles produced are subsequently subjected to a lyophilising step, a filling step in which medicinal gas is introduced and a restoration step of the microbubbles by adding an aqueous solution.

Abstract: A device for providing improved wound healing is described. The device includes a vacuum system for applying a sub-atmospheric pressure to the wound, a gas supply system for applying a gaseous wound healing agent to the wound, and a controller connected with the vacuum system and the gas supply system that controls the applications of the sub-atmospheric pressure and the application of the gaseous wound healing agent to the wound. A method of using the device for improved wound healing is also described.

Abstract: The present invention is directed to methods and compositions for the prevention of citrus greening disease. In one embodiment, there is provided a method for repelling or killing insect vectors of citrus greening disease comprising exposing the vectors to an effective amount of at least one volatile compound set forth in Tables 1 and 2 herein. In one embodiment, the volatile compound is dimethyl disulfide.

Abstract: Topical administration of a generator of H2S in biological tissues for the treatment of eye disorders, such as glaucoma. NaHS caused a time-dependent decrease in intrancular pressure in nomotensive, conscious albino rabbits indicating a similar role for H2S in the regulation of aqueous humor dynamics in animals and humans. H2S donors, NaHS and Na2S, inhibited field-stimulated [3H]NE release from porcine isolated iris-ciliary bodies and produced relaxation of pre-contracted iris muscle strips indicating a pharmacological role for H2S in the anterior uvea. The observation that donors of H2S can alter sympathetic neurotransmission and induce an inhibitory action on iris smooth muscle suggests that this gas has the potential to influence several physiological/pathological processes in the eye. The ability of NaHS or Na2S to inhibit [3H]NE release mimics the well-established action some antiglaucoma drugs (e.g.

Abstract: This invention provides articles of manufacture and bandages comprising compartments and layers comprising oxygen and other therapeutic gas storage forms and perfluorocarbons. This invention also provides for methods of delivering oxygen and other therapeutic gases to a tissue in a subject comprising a administering to the tissue a composition comprising a perfluorocarbon and a oxygen or therapeutic gas storage form, so as to thereby deliver oxygen or the therapeutic gas to the tissue.

Abstract: A method of treating a poison-caused pathology in an individual subject is described which includes administering a pharmaceutical composition including a therapeutically effective amount of a chloride current modulator, a therapeutically effective amount of an exogenous oxygen carrier, or a combination of a therapeutically effective amount of a chloride current modulator and a therapeutically effective amount of an exogenous oxygen carrier, to an individual subject exposed to a poison. Optionally, an inventive method further includes administering a therapeutic agent to inhibit poison-caused pathology. A composition according to the invention is described which includes a therapeutically effective amount of a chloride current modulator, a therapeutically effective amount of an exogenous oxygen carrier, or a combination of a therapeutically effective amount of a chloride current modulator and a therapeutically effective amount of an exogenous oxygen carrier.

Abstract: A composition for energy-controlled generation and release of at least one gas, which includes an energy-activated catalyst capable of being activated by electromagnetic energy, and a solid or a liquid containing anions capable of being oxidized by the activated catalyst or reacted with species generated during activation of the catalyst to generate at least one gas. The composition, when exposed to electromagnetic energy, is capable of generating and releasing the gas after activation of the catalyst and oxidation or reaction of the anions.

Abstract: The present invention concerns the use of active compounds for inducing apnea and treating shock, in addition to enhancing the survivability of a subject. It includes compositions, methods, articles of manufacture and apparatuses for enhancing survivability and for achieving these effects.

Abstract: The present invention provides novel stable, liquid compositions comprising chalcogenides or salts thereof. These compositions may be used for a variety of purposes, including the treatment and prevention of ischemic or hypoxic injury, as well as in the preservation of biological matter.

Abstract: The present invention provides novel stable, liquid compositions comprising chalcogenides or salts thereof. These compositions may be used for a variety of purposes, including the treatment and prevention of ischemic or hypoxic injury, as well as in the preservation of biological matter.

Abstract: Pulmonary disorders in which the GSNO pool or glutathione pool in the lung is depleted and where reactive oxygen species in lung are increased, are treated by delivering into the lung as a gas, agent causing repletion or increase of the GSNO pool or protection against toxicity and does so independently of reaction with oxygen. Agents include ethyl nitrite, NOCl, NOBr, NOF, NOCN, N2O3, HNO, and H2S. Optionally, N-acetylcysteine, ascorbate, H2S or HNO is administered in addition to other GSNO repleting agent to potentiate the effect of said agent.

Abstract: A mineral supplement or feed for ruminant animals, especially deer, contains effective amounts of sulfur and garlic to repel insects from the animals. By inducing the repellant into the animal via ingestion of the mineral supplement or feed, disease and stress in the animals as caused by the insects is reduced.

Abstract: A pest deterrent compound includes water, calcium carbonate and hydrogen sulfide. The compound is successful in deterring white flies and other destructive insects from attacking plants. The plant is protected by pouring a liquid solution onto the plant and the ground underneath and around the plant. The compound is absorbed into the plant's leaves and roots and acts as a deterrent against destructive insects. The pest deterrent compound is given in the following formula.

Abstract: A termiticide which comprises at least one compound which in the presence of a termite produces a termiticidally effective amount of hydrogen sulfide.

Abstract: Pulmonary disorders in which the GSNO pool or glutathione pool in the lung is depleted and where reactive oxygen species in lung are increased, are treated by delivering into the lung as a gas, agent causing repletion or increase of the GSNO pool or protection against toxicity and does so independently of reaction with oxygen. Agents include ethyl nitrite, NOCl, NOBr, NOF, NOCN, N2O3, HNO, and H2S. Optionally, N-acetylcysteine, ascorbate, H2S or HNO is administered in addition to other GSNO repleting agent to potentiate the effect of said agent.

Abstract: The present invention relates to a substantially dry, disposable, personal cleansing article useful for both cleansing the skin or hair, and more particularly to a disposable, cleansing article having a substrate which preferably comprises of multiple layers. These articles are used by the consumer by wetting the dry article with water. The article comprises a water insoluble substrate having at least a first portion that is wet extensible and at least a second portion that is less wet extensible than said first portion and a lathering surfactant. Preferably, the articles of the present invention further comprise a conditioning component.

Abstract: A cosmetic composition in the form of water-in-oil emulsion comprising: (a) a continuous oil phase, (b) a discontinuous phase, and (c) an amino acid salt of salicylic acid or an amino acid salt of a salicylic acid derivative. The composition of the invention provide regulation of the oily and/or shiny appearance of the skin.

Abstract: Stable, topically applicable oil-in-water bioaffecting emulsions having intermediate viscosity, characteristically ranging from 3 to 10 Pa.multidot.s, comprise (a) from 30% to 50% by weight of at least one pro-penetrating glycol, (b) at least one emulsifying agent, advantageously an anionic amphiphilic polymer, and (c) at least one biologically active agent, for example an active agent that modulates skin differentiation and/or proliferation and/or pigmentation, an anti-inflammatory, an antibacterial, an antifungal, etc.

Abstract: A shampoo product is preferably made from boric acid, zinc oxide, starch, and other ingredients.

Abstract: Cosmetic skin conditioning compositions containing ferulyl salicylate. The inventive compositions provide control of sebum secretion from sebocytes, improved oil control and improved skin feel, prevent shine and stickiness, while also providing anti-aging benefits which results in reduced appearance of wrinkles and aged skin, improved skin color, treatment of photoaged skin, improvement in skin's radiance and clarity and finish, and an overall healthy and youthful appearance of the skin.

Abstract: The use of a compound having the formula ##STR1## wherein R represents methyl or ethyl, for regulating the greasiness of the skin, particular novel physical forms of said compound, cosmetic compositions comprising said agent, processes for preparing said agent and compositions, and a method of reducing the greasiness of the skin.

Abstract: Dermatological/cosmetic compositions for reducing or decelerating human hair loss comprise an effective hair loss-reducing amount of combinatory immixture of (a) at least one antifungal agent and (b) at least one halogenated antibacterial agent other than a macrolide or pyranoside, characteristically formulated in a topically physiologically acceptable medium therefor.

Abstract: The invention relates to a cosmetic and/or dermatological composition containing at least one protein selected from proteins of plant origin and animal origin, wherein the protein may or may not be hydrolysed, and at least one crosslinked poly(2-acrylamido-2-methylpropanesulphonic acid) polymer neutralized to at least 90%, and to its uses. The composition comprises, distributed randomly,a) from 90 to 99.9% by weight of units of formula (1): ##STR1## in which X.sup.+ denotes a cation or a mixture of cations, it being possible for at most 10 mol % of the cations X.sup.+ to be protons H.sup.+ ; andb) from 0.01 to 10% by weight of crosslinking units resulting from at least one monomer having at least two olefinic double bonds, the proportions by weight being defined with respect to the total weight of the polymer.

Abstract: The subject invention involves topical depilatory composition at a pH 7 or below, comprising sulfhydryl compounds. The subject invention further relates methods for removing vellus hair from mammalian comprising topical application of a composition, at a pH of 7 or below, comprising a sulfhydryl compound or a cosmetically- and/or pharmaceutically-acceptable salt thereof.

Abstract: The invention relates to a cosmetic or dermatological composition containing at least one active principle precursor capable of releasing an active principle by enzymatic reaction on contact with the Stratum corneum and at least one crosslinked poly(2-acrylamido-2-methylpropanesulphonic acid) polymer neutralized to at least 90% and to its uses. It generally contains, distributed randomly: (a) from 90 to 99.9% by weight of units of formula (1): ##STR1## in which X.sup.+ denotes a cation or a mixture of cations, it being possible for at most 10 mol % of the cations X.sup.+ to be protons H.sup.+ ; and (b) from 0.01 to 10% by weight of crosslinking units resulting from at least one monomer having at least two olefinic double bonds, the proportions by weight being defined with respect to the total weight of the polymer.

Abstract: The present application relates to a cosmetic and/or dermatological composition in the form of a surfactant-free oil-in-water emulsion containing at least one crosslinked poly(2-acrylamido-2-methylpropanesulphonic acid) polymer neutralized to at least 90%. The composition contains, distributed randomly:(a) from 90 to 99.9% by weight of units of formula (1) below: ##STR1## in which X.sup.+ denotes a cation or a mixture of cations, it being possible for not more than 10 mol % of the cations X.sup.+ to be protons H.sup.+ ; and(b) from 0.01 to 10% by weight of crosslinking units originating from at least one monomer having at least two olefinic double bonds, the weight proportions being defined relative to the total weight of the polymer.

Abstract: The use of a compound having the formula ##STR1## wherein R represents methyl or ethyl, for regulating the greasiness of the skin, particular novel physical forms of said compound, cosmetic compositions comprising said agent, processes for preparing said agent and compositions, and a method of reducing the greasiness of the skin.

Abstract: A scalp and hair treatment method and composition wherein the composition comprises deionized water, a vasodilator (such as ethyl nicotinate and/or capsicum extract), a magnesium salt, and a hydrolyzed protein. The composition can be applied on a monthly or bi-monthly basis to the scalp and hair for about 30 minutes and rinsed away with water.

Abstract: A procedure for screening a candidate substance for biological hair care activity comprises (i) microdissecting and isolating at least one viable hair follicle and the epidermal surroundings thereof, while preserving the continuity of such at least one hair follicle and the epidermal environment thereof, but removing the adipose tissue therefrom, (ii) incubating the at least one hair follicle in a nutrient medium for a given period of time, (iii) contacting the at least one incubated hair follicle with the candidate substance for biological hair care activity, and (iv) measuring a marker of the hair care activity of the candidate substance and thence evaluating the results of such measurement in comparison with a control.

Abstract: Dermatological/cosmetic compositions for reducing or decelerating human hair loss comprise an effective hair loss-reducing amount of combinatory immixture of (a) at least one antifungal agent and (b) at least one halogenated antibacterial agent other than a macrolide or pyranoside, characteristically formulated in a topically physiologically acceptable medium therefor.

Abstract: The use of a compound having the formula ##STR1## wherein R represents methyl or ethyl, for regulating the greasiness of the skin, particular novel physical forms of said compound, cosmetic compositions comprising said agent, processes for preparing said agent and compositions, and a method of reducing the greasiness of the skin.

Abstract: A method of treating dandruff in warm-blooded animals comprising applying to the hair of a warm-blooded animal an anti-dandruff effective amount of an alkali metal or ammonium salt of a low molecular weight huminate with a mean molecular weight of 1000 with a range of 300 to 1500 and a method of treating or preventing dandruff.

Abstract: A cosmetically acceptable composition with anti-ache or keratolytic activity comprising: 0.01 to 25% by weight of a keratolytic compound complexed to a carrier molecule, 75-99.95 % by weight of a diluent.